Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa linker

besponsa linker

Перейти к контенту

Главное меню:

besponsa linker
Welcome to BESPONSA® | BESPONSA®, Pfizer’s ADC ambition bolstered by US Besponsa approval, Besponsa - FDA prescribing information, side effects and uses, Inotuzumab ozogamicin - Wikipedia, BESPONSA 1 mg powder for concentrate for solution for , Besponsa New FDA Drug Approval | CenterWatch, EU nod for Pfizer’s Besponsa - PharmaTimes, Mechanism of Action | BESPONSA™ (inotuzumab ozogamicin , Besponsa Monograph for Professionals - Drugs.com.
BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . BESPONSA is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age.. “Besponsa will help address a significant need for new treatment options in B-cell acute lymphoblastic leukemia, and may help more patients reach stem cell transplant, which provides the best chance for long term remission,” said president of Pfizer Oncology, Liz Barrett..
Discontinue Besponsa if low platelet count persists for greater than 28 days and is suspected to be related to Besponsa. If prior to Besponsa treatment ANC was less than 1 × 10 9 /L and/or platelet count was less than 50 × 10 9 /L *. History. In 2017 inotuzumab ozogamicin was approved by the European Commission and the FDA for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in 2017 under the trade name Besponsa (Pfizer/Wyeth).. Nonclinical data suggest that the anticancer activity of BESPONSA is due to the binding of the ADC to CD22-expressing tumour cells, followed by internalisation of the ADC-CD22 complex, and the intracellular release of N-acetyl-gamma-calicheamicin dimethylhydrazide via hydrolytic cleavage of the linker. Activation of N-acetyl-gamma-calicheamicin dimethylhydrazide induces double-stranded DNA . Besponsa (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC). Besponsa is specifically indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.. Besponsa (inotuzumab ozogamicin) consists of a monoclonal antibody targeting CD22, a cell surface antigen expressed on around 90 percent of B-cell malignancies, linked to a cytotoxic agent. When the drug binds to CD22 on malignant B-cells it is taken into the cell, where the cytotoxic agent calicheamicin is released to destroy it.. The linker is cleaved inside the cell, allowing calicheamicin to enter the nucleus. 2. The BESPONSA-bound CD22 antigen is internalized by the cell. 4. Inside the nucleus, calicheamicin induces double-strand DNA breaks that result in apoptosis. 1. BESPONSA binds preferentially to CD22 on the surface of leukemic blasts. 2. The BESPONSA-bound CD22 antigen is internalized by the cell. 3. The .
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню